Filing Overview
Avita Therapeutics, Inc. filed this Form 8-K on August 27, 2020 under Item 2.02 to report the filing of its Appendix 4E Preliminary Final Report with the Australian Securities Exchange for the fiscal year ended June 30, 2020. The report was prepared in U.S. dollars under U.S. GAAP. The company’s common stock traded on Nasdaq under the symbol RCEL.
Financial Results and Condition
The supplied Form 8-K text does not provide revenue, net income or loss, cash flow, margins, debt, liquidity, or other financial metrics. It incorporates the front portion of the Preliminary Final Report as Exhibit 99.1 and identifies the company’s Form 10-K, filed separately on the same date, as the remaining portion of the report.
Material Changes Versus Prior Period
The filing does not state specific year-over-year changes or provide comparable-period financial data.
Outlook, Risks, and Unusual Items
The filing contains no guidance, outlook, management commentary, risk updates, contingencies, or unusual-item disclosures beyond noting the filing of the preliminary fiscal-year results with the ASX.
Investor Verification Items
- Review Exhibit 99.1 for the fiscal 2020 headline results and other disclosures.
- Review the Form 10-K filed August 27, 2020 for complete financial statements, liquidity, debt, cash flow, risks, and year-over-year comparisons.
- Confirm whether the Preliminary Final Report was subsequently finalized or amended.
- Verify the company’s corporate name and trading symbol, as this filing identifies the registrant as Avita Therapeutics, Inc. and the stock symbol as RCEL.